PhD position (m/f/d)

Universitätsklinikum Heidelberg (UKHD); Heidelberg; Vor Ort; EUR 50.000 - 70.000; Vollzeit

Zusammenfassung

Das Universitätsklinikum Heidelberg sucht einen engagierten Wissenschaftler im Bereich Molekularbiologie zur Analyse von tRNA-Modifikationen und deren Auswirkungen auf Leukämiepatienten. Die Rolle beinhaltet die Integration von Daten aus verschiedenen 'Omics' und die funktionale Validierung neuer RNA-Modifikationen in einer kooperativen Forschungsumgebung. Ideale Kandidaten verfügen über einen Masterabschluss, praktische Erfahrungen und eine hohe Motivation zur Arbeit im Team.

Leistungen

Individuelle Fortbildungsmöglichkeiten

Möglichkeit zur Promotion

Attraktive betriebliche Altersvorsorge

30 Tage Urlaub

Familienfreundliche Arbeitsbedingungen

Qualifikationen

• Masterabschluss oder Vergleichbares in relevanten Fachgebieten.
• Erfahrung in Technologien wie PCR, NGS, Zellkultur erforderlich.
• Hohe Motivation und Teamfähigkeit.

Aufgaben

• Analyse von tRNA-Modifikationsniveaus in Leukämiemuster.
• Integration von Multi-Omics-Daten zur Untersuchung vom Behandlungserfolg.
• Funktionale Validierung von RNA-Modifikationen mit CRISPR-Cas9.

Kenntnisse

Molekularbiologie Methoden

Bioinformatik (z.B. R)

Interesse an Krebsbiologie

RNA-Biologie

Stammzellforschung

Ausbildung

Masterabschluss in Molekularbiologie

Jobbeschreibung

Your tasks

• Analyze tRNA modification levels in matched leukemia patient samples collected at diagnosis and relapse, and compare them to healthy hematopoietic specimens using nanopore-based direct tRNA sequencing. Complementary transcriptomic, proteomic, and metabolomic profiling will be performed on the same samples
• Integrate multi-omics data (e.g., using MOFA) to investigate how patient-specific tRNA modification patterns correlate with treatment response and survival
• Functionally validate candidate RNA modifications and their associated enzymes using CRISPR-Cas9 knockouts in both primary healthy and malignant cells, as well as established cell culture models
• Conduct colony-forming unit (CFU) assays, drug synergy screens, ribosome profiling (Ribo-Seq), and nanopore sequencing of modified primary cells and cell lines
• Work in close collaboration with a PhD student from the Frye Lab, particularly on in vivo models and single-cell RNA sequencing (scRNA-seq). Additional collaboration with other research groups within CRC/SFB 1709 is expected
  
  

Your profile

• Master degree (or similar) in molecular biology, biomedicine, biotechnology, bioinformatics or a related field
• Experience in molecular biology methods (e.g. PCR, NGS, cell culture) and/or functional cell assays
• Strong interest in cancer biology, RNA biology, and stem cell research
• Bioinformatics experience, e.g. R, preferred
• High motivation, curiosity, and the ability to work independently and in a team as well as good communication skills in english (written and spoken) are expected
  
  

Your tasks

• Analyze tRNA modification levels in matched leukemia patient samples collected at diagnosis and relapse, and compare them to healthy hematopoietic specimens using nanopore-based direct tRNA sequencing. Complementary transcriptomic, proteomic, and metabolomic profiling will be performed on the same samples
• Integrate multi-omics data (e.g., using MOFA) to investigate how patient-specific tRNA modification patterns correlate with treatment response and survival
• Functionally validate candidate RNA modifications and their associated enzymes using CRISPR-Cas9 knockouts in both primary healthy and malignant cells, as well as established cell culture models
• Conduct colony-forming unit (CFU) assays, drug synergy screens, ribosome profiling (Ribo-Seq), and nanopore sequencing of modified primary cells and cell lines
• Work in close collaboration with a PhD student from the Frye Lab, particularly on in vivo models and single-cell RNA sequencing (scRNA-seq). Additional collaboration with other research groups within CRC/SFB 1709 is expected
  
  

Your tasks

• Analyze tRNA modification levels in matched leukemia patient samples collected at diagnosis and relapse, and compare them to healthy hematopoietic specimens using nanopore-based direct tRNA sequencing. Complementary transcriptomic, proteomic, and metabolomic profiling will be performed on the same samples
• Integrate multi-omics data (e.g., using MOFA) to investigate how patient-specific tRNA modification patterns correlate with treatment response and survival
• Functionally validate candidate RNA modifications and their associated enzymes using CRISPR-Cas9 knockouts in both primary healthy and malignant cells, as well as established cell culture models
• Conduct colony-forming unit (CFU) assays, drug synergy screens, ribosome profiling (Ribo-Seq), and nanopore sequencing of modified primary cells and cell lines
• Work in close collaboration with a PhD student from the Frye Lab, particularly on in vivo models and single-cell RNA sequencing (scRNA-seq). Additional collaboration with other research groups within CRC/SFB 1709 is expected
• Analyze tRNA modification levels in matched leukemia patient samples collected at diagnosis and relapse, and compare them to healthy hematopoietic specimens using nanopore-based direct tRNA sequencing. Complementary transcriptomic, proteomic, and metabolomic profiling will be performed on the same samples
• Integrate multi-omics data (e.g., using MOFA) to investigate how patient-specific tRNA modification patterns correlate with treatment response and survival
• Functionally validate candidate RNA modifications and their associated enzymes using CRISPR-Cas9 knockouts in both primary healthy and malignant cells, as well as established cell culture models
• Conduct colony-forming unit (CFU) assays, drug synergy screens, ribosome profiling (Ribo-Seq), and nanopore sequencing of modified primary cells and cell lines
• Work in close collaboration with a PhD student from the Frye Lab, particularly on in vivo models and single-cell RNA sequencing (scRNA-seq). Additional collaboration with other research groups within CRC/SFB 1709 is expected
  
  

Your profile

• Master degree (or similar) in molecular biology, biomedicine, biotechnology, bioinformatics or a related field
• Experience in molecular biology methods (e.g. PCR, NGS, cell culture) and/or functional cell assays
• Strong interest in cancer biology, RNA biology, and stem cell research
• Bioinformatics experience, e.g. R, preferred
• High motivation, curiosity, and the ability to work independently and in a team as well as good communication skills in english (written and spoken) are expected
• Master degree (or similar) in molecular biology, biomedicine, biotechnology, bioinformatics or a related field
• Experience in molecular biology methods (e.g. PCR, NGS, cell culture) and/or functional cell assays
• Strong interest in cancer biology, RNA biology, and stem cell research
• Bioinformatics experience, e.g. R, preferred
• High motivation, curiosity, and the ability to work independently and in a team as well as good communication skills in english (written and spoken) are expected
  
  

We offer

• Goal-oriented, individual training and development opportunities
• Working with the latest techniques / technical equipment
• Possibility of doctorate
• Possibility to publish scientifically is offered and supported
• Regular team meetings
• Close collaboration within SFB/CRC1709
• Collectively agreed remuneration, attractive company pension scheme (VBL)
• 30 days vacation
• Sustainable travel: job ticket
• Family-friendly working environment: cooperative arrangements for childcare, subsidy for child vacation care, advice for employees with relatives in need of care
• Wide range of health, prevention and sports offers
  
  

We offer

• Goal-oriented, individual training and development opportunities
• Working with the latest techniques / technical equipment
• Possibility of doctorate
• Possibility to publish scientifically is offered and supported
• Regular team meetings
• Close collaboration within SFB/CRC1709
• Collectively agreed remuneration, attractive company pension scheme (VBL)
• 30 days vacation
• Sustainable travel: job ticket
• Family-friendly working environment: cooperative arrangements for childcare, subsidy for child vacation care, advice for employees with relatives in need of care
• Wide range of health, prevention and sports offers
• Goal-oriented, individual training and development opportunities
• Working with the latest techniques / technical equipment
• Possibility of doctorate
• Possibility to publish scientifically is offered and supported
• Regular team meetings
• Close collaboration within SFB/CRC1709
• Collectively agreed remuneration, attractive company pension scheme (VBL)
• 30 days vacation
• Sustainable travel: job ticket
• Family-friendly working environment: cooperative arrangements for childcare, subsidy for child vacation care, advice for employees with relatives in need of care
• Wide range of health, prevention and sports offers
  
  

Contact & Application

For further information please contact Cornelius Pauli via e-mail.

Interested?

Applications will be accepted until 10.08.2025 direct online.

Klinik für Hämatologie, Onkologie und Rheumatologie

Dr. Cornelius Pauli

Im Neuenheimer Feld 410

69120 Heidelberg

Tel.: [phone]

[e-mail]

For further information please contact Cornelius Pauli via e-mail.

Interested?

Applications will be accepted until 10.08.2025 direct online.

Klinik für Hämatologie, Onkologie und Rheumatologie

Dr. Cornelius Pauli

Im Neuenheimer Feld 410

69120 Heidelberg

Tel.: [phone]

[e-mail]